Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Atezolizumab administered concurrently with chemoradiation failed to improve OS and PFS outcomes compared with standard chemoradiation alone in LS-SCLC.

Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC

MRD negativity was sustained at 1 year following the cessation of maintenance lenalidomide in multiple myeloma.

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma

Binod Dhakal, MD, discusses survival data with ciltacabtagene autoleucel in lenalidomide-refractory relapsed/refractory multiple myeloma.
 

Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

The OncFive: Top Oncology Articles for the Week of 9/29

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Yuan Yuan, MD, PhD, discusses the management of node-positive breast cancer and the need for guidance surrounding the use of ctDNA in breast cancer.

Research Seeks to Establish the Efficacy of Minimally Invasive Breast Cancer Procedures and Tests

 
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource 

. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Here is your snapshot of all treatment options that the FDA approved in September 2024.

OncLive’s September Roundup of Key FDA Approvals in Oncology

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

School of Breast Oncology

Latest Conference Coverage